
A study compared nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) with gemcitabine and cisplatin as first-line treatments for recurrent or metastatic nasopharyngeal carcinoma. Participants (≥18 years) were randomized 1:1 to receive either nab-TPC or gemcitabine and cisplatin. The primary endpoint, progression-free survival evaluated by an independent review committee, showed a median of 11.3 months (95% CI 9.7 to 12.9) with nab-TPC versus 7.7 months (6.5 to 9.0) with gemcitabine and cisplatin (HR 0.43, 95% CI 0.25 to 0.73; P=0.002). Nab-TPC also demonstrated higher objective response rates (83% vs. 63%) and longer duration of response (10.8 vs. 6.9 months) compared to gemcitabine and cisplatin. The study concludes that nab-TPC is a more effective and safer first-line treatment for this patient group, pending confirmation of overall survival benefits with longer-term follow-up.
Like
Save
Share